Mendacious
发表于 2025-3-25 05:16:20
Jeffrey M. Bumpous,Mary Worthenors is also different for this sub-family, requiring klotho protein cofactors rather than heparin sulfate proteoglycan. Mouse Fgf15 and human FGF19 play key roles in enterohepatic signaling, regulation of liver bile acid biosynthesis, gallbladder motility and metabolic homeostasis.
Comedienne
发表于 2025-3-25 11:00:52
,Klotho and βKlotho,rs and exert their biological activities. This chapter overviews function of Klotho family proteins as obligate coreceptors for endocrine FGFs and discusses potential link between Klothos and age-related diseases.
CUB
发表于 2025-3-25 12:10:22
http://reply.papertrans.cn/31/3098/309715/309715_23.png
逃避现实
发表于 2025-3-25 18:03:53
http://reply.papertrans.cn/31/3098/309715/309715_24.png
Detoxification
发表于 2025-3-25 20:05:08
http://reply.papertrans.cn/31/3098/309715/309715_25.png
褪色
发表于 2025-3-26 00:47:07
http://reply.papertrans.cn/31/3098/309715/309715_26.png
修剪过的树篱
发表于 2025-3-26 07:42:13
Evidence for FGF23 Involvement in a Bone-Kidney Axis Regulating Bone Mineralization and Systemic Phs through yet-to-be defined locally derived factors. In addition, FGF23 production is regulated by 1,25(OH)2D in a feedback loop where FGF23 stimulate Cyp24 mediated degradation of 1,25(OH)2D that serves to protect the organism from the toxic effects of vitamin D excess. In this chapter, we will review the regulation and function of FGF23.
和音
发表于 2025-3-26 08:34:54
Book 2012 affinity to FGF receptors in their target organs, the endocrine FGFs have designated the Klotho family of transmembrane proteins as obligate co-receptors. By expressing Klothos in a tissue-specific manner, this unique co-receptor system also enables the endocrine FGFs to specify their target organs among many tissues that express FGF receptors.
PRO
发表于 2025-3-26 15:07:12
http://reply.papertrans.cn/31/3098/309715/309715_29.png
collateral
发表于 2025-3-26 17:51:39
https://doi.org/10.1007/978-3-662-33866-7 and lack of apparent side effects in a variety of animal models. Thus, FGF21 represents a novel and appealing therapeutic reagent for Type 2 diabetes mellitus, obesity, dyslipidemia, cardiovascular and fatty liver diseases. The in vitro biology, genetic animal models and in vivo pharmacology of FGF21 will be discussed in this chapter.